{"id":"placebo-for-aflibercept","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"As a placebo, it does not contain any active pharmaceutical ingredient and therefore does not have a known mechanism of action. It is used as a control in clinical trials to compare the efficacy of active treatments.","oneSentence":"Placebo does not have a known mechanism of action.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:04.483Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Comparison control in clinical trials for aflibercept"}]},"trialDetails":[{"nctId":"NCT03845049","phase":"PHASE3","title":"Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2019-07-03","conditions":"Macular Telangiectasia","enrollment":16},{"nctId":"NCT02462889","phase":"PHASE2","title":"IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD","status":"COMPLETED","sponsor":"Jeffrey S Heier","startDate":"2015-06","conditions":"Age-Related Macular Degeneration","enrollment":128},{"nctId":"NCT00532155","phase":"PHASE3","title":"A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-09","conditions":"Carcinoma, Non Small Cell Lung","enrollment":913},{"nctId":"NCT03802630","phase":"PHASE3","title":"Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-07-02","conditions":"Branch Retinal Vein Occlusion","enrollment":450},{"nctId":"NCT03810313","phase":"PHASE3","title":"Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-07-03","conditions":"Central Retinal Vein Occlusion","enrollment":493},{"nctId":"NCT04331730","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD","status":"COMPLETED","sponsor":"Alkahest, Inc.","startDate":"2020-01-28","conditions":"Neovascular Age-related Macular Degeneration","enrollment":107},{"nctId":"NCT02348359","phase":"PHASE2","title":"X-82 to Treat Age-related Macular Degeneration","status":"TERMINATED","sponsor":"Tyrogenex","startDate":"2015-03-16","conditions":"Age-Related Macular Degeneration (AMD), Macular Degeneration, Exudative Age-related Macular Degeneration","enrollment":157},{"nctId":"NCT01747551","phase":"PHASE2","title":"FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-01","conditions":"Esophageal Cancer, Gastric Cancer","enrollment":64},{"nctId":"NCT01661270","phase":"PHASE3","title":"A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-07","conditions":"Colorectal Cancer Metastatic","enrollment":332},{"nctId":"NCT01414153","phase":"PHASE2","title":"Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD","status":"COMPLETED","sponsor":"Lpath, Inc.","startDate":"2012-08","conditions":"Exudative Age-related Macular Degeneration","enrollment":158},{"nctId":"NCT00519285","phase":"PHASE3","title":"Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-08","conditions":"Prostatic Neoplasms, Neoplasm Metastasis","enrollment":1224},{"nctId":"NCT00574275","phase":"PHASE3","title":"Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer","status":"TERMINATED","sponsor":"Sanofi","startDate":"2007-12","conditions":"Pancreatic Neoplasm","enrollment":546},{"nctId":"NCT01868360","phase":"PHASE1","title":"Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea","status":"TERMINATED","sponsor":"Balamurali Ambati","startDate":"2013-06","conditions":"Corneal Neovascularization","enrollment":2},{"nctId":"NCT01754272","phase":"","title":"A Non-Interventional Follow-Up to the VELOUR Study - Translational Research","status":"UNKNOWN","sponsor":"KU Leuven","startDate":"2012-01","conditions":"Metastatic Colorectal Cancer","enrollment":1226},{"nctId":"NCT00561470","phase":"PHASE3","title":"Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-11","conditions":"Colorectal Neoplasms, Neoplasm Metastasis","enrollment":1226}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":64,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo (for aflibercept)","genericName":"Placebo (for aflibercept)","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo does not have a known mechanism of action. Used for Comparison control in clinical trials for aflibercept.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}